Halozyme Therapeutics, Inc.
Moat Score — Halozyme Therapeutics, Inc.
Total Moat Score
16 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Halozyme's patented rHuPH20 recombinant hyaluronidase enzyme and the ENHANZE platform built around it are proprietary biologic technology that major pharma partners cannot simply replicate, and the company holds the core IP outright. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Halozyme owns no manufacturing facility and relies entirely on contract manufacturers like Avid and Catalent, giving it no structural cost advantage and real supply-chain dependency risk. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Target designation fees, milestone payments, and ongoing sales royalties across eleven ENHANZE collaborations show real negotiating leverage with partners who need the technology, though royalty rates are ultimately set through negotiated partner contracts rather than open pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Each ENHANZE partnership operates independently; one partner's use of the technology does not make it more valuable to another partner, so there is no network effect in the licensing business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once a partner has designed ENHANZE into an approved drug's formulation and regulatory filing, switching to an alternative subcutaneous delivery technology would require costly re-formulation and new clinical trials, locking in royalty relationships for the life of the approved product. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Enabling subcutaneous delivery technology for biologics is a narrow, technically demanding niche with few credible platform competitors, letting Halozyme's rHuPH20 serve as the default choice for pharma partners rather than facing constant competitive bidding. |